Sana Biotechnology (SANA) stock surges 12.1% on positive results for type 1 diabetes treatment.

From Yahoo Finance.: 2025-06-29 03:03:00

Sana Biotechnology (SANA) stock surged 12.1% on June 23 after positive six-month follow-up results from a first-in-human study of its type 1 diabetes treatment. The therapy, UP421, uses cadaver-sourced pancreatic islet cells genetically modified to evade immune detection, showing safety, tolerance, and insulin production without immunosuppression.

Study results suggest a potential functional cure for type 1 diabetes without immunosuppression is possible. Sana Biotechnology develops engineered cell therapies for serious diseases like cancer, type 1 diabetes, and genetic disorders. The company’s platforms include hypoimmune cells, gene delivery, and in vivo cell engineering.

While Sana Biotechnology (SANA) shows promise, consider other AI stocks with greater upside potential and lower downside risk. For opportunities in undervalued AI stocks benefiting from tariffs and onshoring trends, explore Insider Monkey’s report on the best short-term AI stock.

Read more: Sana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment Results